Tarnoff Michael E 4
4 · AVITA Medical, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
AVITA Medical (RCEL) Director Michael Tarnoff Receives RSUs & Options
What Happened Michael E. Tarnoff, a director of AVITA Medical, received equity awards that the company reports as (A) awards/grants: 48,464 restricted stock units (RSUs) and options covering 35,196 shares. The option grants carry exercise prices of $5.36 (19,063 options, grant date Aug 6, 2025) and $3.77 (16,133 options, grant date Jan 20, 2026). The RSU grants were for 26,250 shares (Aug 6, 2025) and 22,214 shares (Jan 20, 2026). The Form 4 records the derivative/option amounts at $0 (typical for newly issued option awards) and shows shareholder approval was obtained on June 3, 2026.
Key Details
- Transaction dates listed: Aug 6, 2025 (26,250 RSUs; 19,063 options) and Jan 20, 2026 (22,214 RSUs; 16,133 options).
- Shareholder approval for these grants was obtained on June 3, 2026; Form 4 filed June 4, 2026 (period of report 2026-06-03).
- Option exercise prices: $5.36 (Aug 6, 2025 grant) and $3.77 (Jan 20, 2026 grant).
- Vesting: RSUs vest in three equal annual installments beginning 12 months after the grant; options vest in three equal annual installments beginning the first anniversary of the grant.
- Shares owned after the transactions are not specified in the provided filing excerpt.
- Transaction code: A = Award/Grant; derivative awards shown with $0 reported value (common for grant reporting).
- Filing appears timely relative to the shareholder approval date (filed the next business day).
Context These are grant-type awards (not open-market purchases or sales). RSUs are a promise to issue shares subject to vesting; stock options give the right to buy shares at the stated exercise prices and will only create an immediate economic interest if exercised (and possibly sold). Such awards are routine compensation for directors and do not, by themselves, indicate a near-term purchase or sale of shares.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2025-08-06+26,250→ 26,250 total - Award
Common Stock
[F3][F2]2026-01-20+22,214→ 48,464 total - Award
Stock Options (Right to Buy)
[F4][F5]2025-08-06+19,063→ 19,063 totalExercise: $5.36Exp: 2035-08-06→ Common Stock (19,063 underlying) - Award
Stock Options (Right to Buy)
[F6]2026-01-20+16,133→ 16,133 totalExercise: $3.77From: 2027-01-20Exp: 2036-01-20→ Common Stock (16,133 underlying)
Footnotes (6)
- [F1]Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- [F2]Includes unvested RSUs
- [F3]Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- [F4]On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- [F5]These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
- [F6]On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.